Efficacy and safety of perampanel in Parkinson’s disease. A systematic review with meta-analysis

Combination Therapy with Zonisamide and Antiparkinson Drugs for Parkinson’s Disease: A Meta-Analysis

(2017) Shinji Matsunaga et al.   JOURNAL OF ALZHEIMERS DISEASE

Oral and intravenous steroids for multiple sclerosis relapse: a systematic review and meta-analysis

(2017) Simona Lattanzi et al.   JOURNAL OF NEUROLOGY

Brivaracetam add-on for refractory focal epilepsy

(2016) Simona Lattanzi et al.   NEUROLOGY

Increased CSF biomarkers of angiogenesis in Parkinson diseaseAuthor Response

(2016) Simona Lattanzi et al.   NEUROLOGY

Perampanel in Parkinson Disease Fluctuations

(2012) Olivier Rascol et al.   CLINICAL NEUROPHARMACOLOGY

Glutamate Receptors as Therapeutic Targets for Parkinsons Disease

(2012) Kari Johnson et al.   CNS & Neurological Disorders-Drug Targets

Perampanel, an AMPA antagonist, found to have no benefit in reducing “off” time in Parkinson's disease

(2011) Andrew Lees et al.   MOVEMENT DISORDERS

Safety and efficacy of perampanel in advanced Parkinson's disease: A randomized, placebo-controlled study

(2010) Karla Eggert et al.   MOVEMENT DISORDERS

A Role for Calcium-Permeable AMPA Receptors in Synaptic Plasticity and Learning

(2010) Brian J. Wiltgen et al.   PLoS One

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

(2009) Etienne C Hirsch et al.   LANCET NEUROLOGY

NMDA antagonist memantine improves levodopa-induced dyskinesias and “On-off” phenomena in Parkinson's disease

(2009) Sara Varanese et al.   MOVEMENT DISORDERS

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Pathophysiology of Parkinsonism

(2008) Adriana Galvan et al.   CLINICAL NEUROPHYSIOLOGY